Hopman Mark's Form 4/A amendment
AmendedBeta Bionics, Inc. (BBNX) · filed Mar 13, 2026
- Accession no.
- 0002048497-26-000003
- Filed
- Mar 13, 2026
- Trade date
- Feb 27, 2026
- Filing delay
- 14 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Mar 3, 2026
This filing lists 1 derivative transaction. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $10.3K. It was filed 14 days after the trade.
This amendment restates part of 0002048497-26-000001 (filed Mar 3, 2026). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hopman MarkCIK 0002048497 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +91,520 | $0.00 | $0 | 91,520 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0002048497-26-000001 (filed Mar 3, 2026).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +109,105 | $0.00 | $0 | 140,320 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −834 | $12.36F3 | −$10,308.24 | 139,486 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F3
The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.
Remarks
The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.